Insights from Prothena's Q4 2024 call highlight 2025 milestones: pivotal trial results for birtamimab & Alzheimer's programs.

Researchers indicate that the Lumipulse p-tau217 assay may reduce over 50% of lumbar punctures performed for diagnosing ...

The MOCA Geffen is spotlighting two major crowd-pullers: Olafur Eliasson ’s seductive light installation OPEN, on view ...

Aharon, Ph.D., Co-Founder & CEO of AEYE Health, in conversation with Jake Laznik, Senior Breaking News Desk Manager, The ...

Scientists have identified a biomarker for Alzheimer's that may help doctors spot the early signs of protein buildup in the ...

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary ...

A research team from the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) has discovered that the two key pathological hallmarks of Alzheimer's—tau protein and beta ...

Furthermore, glymphatic dysfunction may play a role in post-stroke epileptogenesis and cognitive impairment (46), potentially through glutamate excitotoxicity and amyloid-beta/tau deposition. EPVS ...

JERUSALEM, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha ...

Tau hyperphosphorylation and conformational changes in the brain parenchyma start around seven months. Tangle-like pathology is mainly observed in the brain stem and spinal cord, and to a lesser ...